Anesthesiology

The study find that the Percutaneous ultrasound-guided breast cryoablation is a minimally invasive technique that kills targeted tissue with extreme cold; therefore requires only local anesthesia; and takes less than 45 minutes to complete Breast cryoablation using percutaneous ultrasound (US) guidance is a minimally invasive technique that kills target tissue with extreme cold. The procedure requires only local anesthesia and takes less than 45 minutes to complete.

Complete Breast cryoablation

Recovery time is short; making the procedure comfortable and convenient for patients. Cryoablation has been use in the breast to treat fibroadenomas and cancers for over a decade. Treated fibroadenomas show mean volume reduction of 73–89%, with patients noting resolution of palpable mass effect and good cosmesis 12 months after the procedure.

For breast cancer; successful tumor ablation ranging from 85% to 100% for invasive ductal carcinomas (IDC) up to 2 cm in size and 100% success for IDC smaller than 1 cm have been reported . Two ongoing clinical trials are investigating the efficacy of cryoablation without surgical excision for treatment of early-stage breast cancer US-guided breast cryoablation can be used to treat benign fibroadenomas and primary breast cancer.

Primary breast cancer

Some investigators have performed cryoablation for benign papillomas as an alternative to surgical excision (Englander BS, personal communication). To our knowledge; cryoablation and other ablative modalities have not been used to treat other high-risk lesions. Treatment of fibroadenomas by US-guided cryoablation is indicated; for patients with symptoms such as pain and palpability .

The procedure may be particularly applicable for patients with multiple symptomatic fibroadenomas who have already undergone surgical excision or ; who prefer nonsurgical treatment. US-guided cryoablation of breast cancer is usually reserve for patients with IDC. Patients with pure ductal carcinoma in situ (DCIS) ; or IDC with an extensive intracranial component (EIC) have largely been exclude because pure DCIS often has no US correlate and because DCIS may extend outside of the US-targeted ablation zone .

Applicable for patients

Similarly, because the extent of invasive lobular carcinoma (ILC) ; may be underestimated on imaging, ILC has typically been excluded from cryoablation. The ideal candidate for US-guided cryoablation of breast cancer is a low-grade IDC
smaller than 1.5 cm without an EIC that is hormone receptor–positive and HER2-negative ;(also known as ERBB2-negative).

Hormone receptor–positive and HER2-negative breast cancers tend to be biologically less aggressive; lower grade tumors and are less likely to be multifocal, multicentric, and contralateral. Masses best suited for cryoablation are located at least 5 mm and ideally 1 cm from the skin and are well visualize as discrete masses on ultrasound.